

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



PCT

M

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/62, C07K 19/00, A61K 39/00, 48/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/44129</b> <b>(43) International Publication Date:</b> 8 October 1998 (08.10.98)
<b>(21) International Application Number:</b> PCT/AU98/00208 <b>(22) International Filing Date:</b> 26 March 1998 (26.03.98) <b>(30) Priority Data:</b> PO 5891 27 March 1997 (27.03.97) AU PP 1830 13 February 1998 (13.02.98) AU <b>(71) Applicants (for all designated States except US):</b> THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 300 Herston Road, Herston, QLD 4029 (AU). COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION [AU/AU]; Limestone Avenue, Campbell, ACT 2601 (AU). THE UNIVERSITY OF MELBOURNE [AU/AU]; Royal Parade, Parkville, VIC 3052 (AU). THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU/AU]; Royal Melbourne Hospital, Royal Parade, Parkville, VIC 3052 (AU). CSL LIMITED [AU/AU]; 45 Poplar Road, Parkville, VIC 3052 (AU). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BOYLE, Jefferey, Stephen [AU/AU]; 162 Brown Street, Heidelberg, VIC 3084 (AU). BRADY, Jamie, Louise [NZ/AU]; 4 Oamaru Street, North-	<b>cote, VIC 3070 (AU). LEW, Andrew, Mark [AU/AU]; 13 Warner Street, Essendon, VIC 3040 (AU).</b> <b>(74) Agent:</b> F.B. RICE & CO.; 605 Darling Street, Balmain, NSW 2041 (AU). <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> ENHANCEMENT OF IMMUNE RESPONSE USING TARGETING MOLECULES <b>(57) Abstract</b> <p>The present invention provides methods of enhancing the immune response to an immunogen and to compositions for use in these methods. In particular the present invention provides a DNA molecule for use in raising an immune response to an antigen. The DNA molecule includes a first sequence encoding a targeting molecule, a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerisation or multimerisation of the product encoded by the DNA molecule.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## *Enhancement of Immune Response Using Targeting Molecules*

### **FIELD OF THE INVENTION**

5           The present invention relates to methods of enhancing the immune response to an immunogen and to compositions for use in these methods. In particular the present invention relates to the use of targeting molecules in DNA and protein vaccination.

### **10 BACKGROUND OF THE INVENTION**

          The ability of direct injection of non-replicating plasmid DNA coding for viral proteins to elicit protective immune responses in laboratory and preclinical models has created increasing interest in DNA immunisation. A  
15       useful review of DNA vaccination is provided in Donnelly *et al*, Journal of Immunological Methods 176 (1994) 145-152, the disclosure of which is incorporated herein by reference.

          Intramuscular injection of DNA as a means of vaccination can induce both cellular and humoral responses (1). Studies using reporter proteins  
20       demonstrated that muscle cells are the principal target for transfection after intramuscular DNA injection (2). The mechanisms underlying the induction of immune responses after DNA immunisation are unclear. Since myocytes express MHC Class I at low levels and do not constitutively express Class II or costimulatory molecules such as B-7 (3), they appear unlikely candidates  
25       for the induction of Ab or CTL responses. It is possible that low level transfection of antigen presenting cells (APCs) occurs at the injection site and these APCs then traffic to lymphoid organs and present the encoded antigen to B and T cells (4) as has been shown after intradermal (5) and biolistic DNA immunisation (6). Alternatively the myocyte may act merely  
30       as a source of antigen and priming occurs in the draining lymph node. In the latter case, optimum immune induction would result if the antigen was released from the myocyte by secretion or subsequent to cell damage.

          One strategy that has been shown to augment the response to polynucleotide, or DNA, vaccination is the use of sequences encoding  
35       cytokines or co-stimulatory molecules (Conry *et al*, (1996) Gene Therapy

3: 67-74). These investigators showed an increased response when the DNA administered encoded not only the antigen of interest but also for B7-1.

The present inventors investigated the effects of modifying the antigen such that it will be targeted to APC or sites of immune induction. This was  
5 shown to not only markedly enhance the immune response but also cause immune deviation.

## SUMMARY OF THE INVENTION

10 In a first aspect the present invention consists in a DNA molecule for use in raising an immune response to an antigen, the DNA molecule including a first sequence encoding a targeting molecule, a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerisation or multimerisation of  
15 the encoded product.

As will be appreciated by those skilled in the art in a number of instances the antigen or epitope encoded by the second sequence will be a polypeptide which promotes dimerisation or multimerisation of the encoded product. As will be understood in such instances the third sequence may be  
20 omitted.

In a second aspect the present invention consists in a polypeptide, the polypeptide being encoded by the DNA molecule of the first aspect of the invention.

In a third aspect the present invention consists in a method of raising  
25 an immune response in an individual, the method comprising administering to the individual the DNA molecule of the first aspect of the present invention or the polypeptide of the second aspect of the present invention.

There are a wide range of molecules which could be used as targeting molecules. These include ligands which target lymphoid cells (which will  
30 either be at or take the Ag to sites of immune induction), lymphoid sites (eg. spleen, lymph nodes, Peyers patches) or APCs directly. Examples of such ligands include, but are not limited to, CD40L, OX40, antibodies to receptors on APCs (eg. DEC 205, CD 23, CD11c, MHC class II), CD28, CTLA4 and L-selectin. It is presently preferred that the targeting molecule is CTLA4 or  
35 L-selectin.

In a fourth aspect the present invention consists in a method of deviating the immune response to an antigen in an individual, the method comprising administering to the individual a DNA molecule including a first sequence encoding CTLA4, a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerisation or multimerisation of the encoded product.

There are many ways of producing dimerisation or multimerisation including tandem duplication and the use of any molecule that normally forms multimers (e.g. Immunoglobulins, CD8, TNF, glutathione s-transferase, zinc finger dimers etc). There are many references in the scientific literature regarding this area. These include Classon BJ et al (1992) "The hinge region of the CD8 alpha chain: structure, antigenicity, and utility in expression of immunoglobulin superfamily domains" *Int Immunol* 4:215-25; Yang J, Moyana T, Xiang J (1995) "A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor." *Mol Immunol.* 32:873-81; Tudyka T, Skerra A (1997) "Glutathione s-transferase can be used as a c-terminal, enzymatically active dimerization module for a recombinant protease inhibitor, and functionally secreted into the periplasm of *Escherichia coli*." *Protein Science.* 6:2180-2187; Pomerantz JL, Wolfe SA, Pabo CO (1998) "Structure-based design of a dimeric zinc finger protein" *Biochemistry* 37:965-970; and Whiteheart SW, Rossmagel K, Buhrow SA, Brunner M, Jaenicke R, Rothman JE (1994) "N-ethylmaleimide-sensitive fusion protein: a trimeric ATPase whose hydrolysis of ATP is required for membrane fusion." *J Cell Biol* 126:945-54. The disclosure of these references and the other references referred to in this application are included herein by cross-reference.

As will be appreciated by those skilled in the art in the constructs of the present invention the first, second and third DNA sequences may be in any particular order. It is presently preferred that the order is first, third then second.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

**DETAILED DESCRIPTION OF THE INVENTION**

In order that the nature of the present invention may be more clearly understood preferred forms thereof will now be described with reference to  
5 the following examples and Figures in which:

Figure 1. Secretion of  $\Delta$ Ig, CTLA4Ig and L-SELIg proteins from NIT transfectants. NIT cells were transfected with the pRep10::CD5L-hIg, pRep7::mCTLA4-hIg and pRep10::hL-SEL-hIg expression plasmids. Secreted  
10 protein was purified on immobilised protein A and samples run by SDS PAGE under reducing and non-reducing conditions.

Figure 2. hIg specific IgG responses in DNA immunized mice. Sera were obtained from BALB/c mice immunized with pRep10::CD5L-hIg, pRep7::mCTLA4-hIg and pRep10::hL-SEL-hIg at the indicated times post  
15 immunisation and stored at -20°C until assayed for hIg specific IgG in an ELISA. Titres were defined as the highest dilution to give a 0.2 OD at 450 nm. Results are expressed as the mean of the log titre  $\pm$ SEM from 5 mice in each group. Normal mouse sera and hyperimmune mouse sera served as the negative and positive controls respectively.

Figure 3. hIg specific IgG subclass responses in DNA immunized mice. A. Sera were obtained from BALB/c mice immunized with pRep10::CD5L-hIg, pRep7::mCTLA4-hIg and pRep10::hL-SEL-hIg at 8 weeks post immunisation and stored at -20°C until assayed for hIg specific IgG1, IgG2a or IgG2b in an ELISA. Titres were defined as the highest dilution to  
25 reach an OD of 0.2 at 450 nm. Results are expressed as the mean of the log titre  $\pm$ SEM from 5 mice in each group. B. The log IgG1 titre for each mouse was divided by the corresponding log IgG2a titre to obtain a log IgG1: log IgG2a ratio. Results are expressed as the mean  $\pm$ SEM from 5 mice in each group.

Figure 4. hIg specific IgG subclass responses in soluble protein immunized mice. Sera were obtained from BALB/c mice immunized with 5  $\mu$ g of hIg or 5  $\mu$ g of CTLA4Ig protein in 100  $\mu$ l of PBS, 2 weeks post immunisation and assayed for hIg specific IgG in an ELISA. Titres were defined as the highest dilution to reach an OD of 0.2 at 450 nm. Results are  
35 expressed as the mean of the log titre  $\pm$ SEM from 5 mice in each group.

Figure 5. hIg specific IgG subclass responses in CTLA4Ig DNA immunized mice. Sera were obtained from BALB/c mice immunized with the indicated dose of pRep7::mCTLA4-hIg 2 weeks post immunisation and assayed for hIg specific IgG1, IgG2a or IgG2b in an ELISA. Titres were defined as the highest dilution to reach an OD of 0.2 at 450 nm. Results are expressed as the mean of the log titre  $\pm$  SEM from 5 mice in each group.

Figure 6. OVA specific IgG and IgG subclass responses after co-injection of DNA. Sera were obtained from BALB/c mice immunized with pRep10::hL-SEL-hIg and pCI-OVA or pRep7::mCTLA4-hIg and pCI-OVA at 4 weeks post immunisation and assayed for OVA specific IgG (A) or IgG1, IgG2a or IgG2b (B) in an ELISA. Titres were defined as the highest dilution to reach an OD of 0.2 at 450 nm. Results are expressed as the mean of the log titre  $\pm$  SEM from 5 mice in each group.

Figure 7. Shows stimulation index with hIg, Lsel-hIg and CTLA4-hIg ( ▨ HuIg 1mg/ml; ▩ HuIg 1mg/ml; ■ HuIg 1mg/ml)

Figure 8. Shows anti-ovalbumin IgG titres with various constructs ( ▩ 2 weeks; ■ 4 weeks)

Figure 9. Shows anti-OVA IgG titres with pCI::mCTLA4-g3h-OVA and pCI::mCTLA4-hIg-OVA

Figure 10. Groups of 5 Balb/c mice were vaccinated intramuscularly on days 0 and 28 with 0.1mg of pCI::mCTLA4-hIg-45W (black circles) or pCI::CD5L-hIg-45W (grey circles). Mice were bled on days 0, 7, 14, 28, 35 and 42. Sera was assayed for anti-45w antibodies by ELISA using recombinant 45W(His)6. The Student's t-test was used to compared the two groups and the probability values (P) for the two vaccines at each time point are shown at the top of the figure.

Figure 11. Groups of 5 Balb/c mice were vaccinated either intraperitoneally with 20 $\mu$ g of recombinant 45w(His)6 protein (grey circles ) in Freund's complete adjuvant or intramuscularly with 0.1mg pCI::mCTLA4-hIg-45W (black circles) in 0.1ml of saline. Mice were bled on days 0, 2, 5, 8, 14 and 28 post-vaccination and anti-45w antibodies measured by ELISA using 45W(His)6 protein. The responses were compared by Student's t-test and were different at day 8 ( $p < 0.05$ ).

Figure 12. Shows % survival of mice following challenge with *Plasmodium chabaudi adami* DS ( ▨ pCI::CD5LhIg-AMA; ▩ pCI::CTLA4-hIg-AMA; ■ pCI::CTLA4-hIg).

Figure 13 shows antibody titres.

Figure 14 shows antibody titres at day 14 with varying immunisations

Figure 15 shows antibody titres at day 54 with varying immunisations

Figure 16 shows lung virus titres

5        Figure 17. Kinetics of induction of the anti-hIg antibody titres  
post-immunisation. Filled symbols represent plasmids containing hIg: filled  
squares (pCI::bCTLA4-hIg-ΔPLD), filled circles (pCI::CD5L-hIg-ΔPLD), filled  
triangles (pCI::bCTLA4-hIg). Open symbols represent control animal groups  
not injected with hIg in any form: open circles (pCI::ΔPLD), open squares  
10    (Unvaccinated controls) and open triangles (Glan-Vac).

Figure 18. Western Blot of PLD expressed by eukaryotic and  
prokaryotic cells. Lane 1-3. Supernatant from Cos-m6 cells transfected with  
pCI::PLD (lane 1), pCI::ΔPLD (lane 2) and pCI alone (lane 3). Lane 4. Cell  
filtrate containing PLD expressed from *Corynebacterium pseudotuberculosis*

15        Figure 19. Protection from challenge with *Corynebacterium*  
*pseudotuberculosis*. Percentage of the animals protected from challenge by  
 $10^6$  CFU of *Corynebacterium pseudotuberculosis* injected just above the  
coronet. Protection was defined as the animal not having abscesses in any of  
the following lymph nodes: popliteal, inguinal and prefemoral both left and  
20    right.

Figure 20 Shows number of mice with lesions at various time points  
after challenge with *L. major* (□ PBS; ▲ pCI::CD5L-hIg-PSA2;  
■ pCI::mCTLA4-hIg-PSA2; Δ pCI::PSA2)

## 25    **EXAMPLE 1**

### *Materials and Methods*

#### Mice

30        Female mice (BALB/c, CBA and C57Bl/6) aged 6 to 8 weeks were used  
in all experiments. Mice were maintained in SPF conditions.

#### Plasmids and immunisations

35        Expression plasmids were constructed to produce secreted forms of  
the Fc fragment of human IgG1 (ΔIg) by using the Cd5 leader sequence  
(CD5L) either alone or fused with murine CTLA4 (mCTLA4Ig) or human



L-selectin (hL-SELIg) under the control of the RSV promoter in the Rep7 or Rep10 vectors (these vectors differ only in the direction of the multiple cloning site, Invitrogen, San Diego, CA, USA). The sequence of pREP7::CTLA4-hIg is shown in Sequence ID No. 1 - Promoter RSV: 13-640, CTLA4-hIg: 703-2462. The constructs were obtained from plasmids given by  
5 Drs. P. Lane (Basel Institute, Switzerland), B. Seed (Massachusetts General Hospital, Boston, USA) and D. L. Simmons (Institute of Molecular Medicine, Oxford, UK). The following constructs were generated:

pRep10::CD5T-hIg  
10 pRep7::mCTLA4-hIg  
pRep10::hLSEL-hIg

Plasmids for injection were prepared from *E. coli* by PEG precipitation as described (7) except that volumes of Solution I, II and III were adjusted such that pellets were resuspended in 50 mL of Solution I for each Litre of  
15 broth media used. Endotoxin was removed from plasmid preparations by four Triton X-114 phase separations (8) and DNA was stored at -20°C in normal saline until injected. The resultant plasmid preparations contained less than 10 IU endotoxin per mg of plasmid DNA as determined by the limulus amoebocyte lysate assay (QCL -1000 BioWhittaker, Walkersville,  
20 MD, USA). Mice received 100 µg of plasmid DNA in both quadriceps or intradermally at the base of the tail on day 0 and 14 of each experiment.

#### Antibody assays

Microtitre plates (Dynatech, Chantilly, VI, USA) were coated with  
25 human Ig (hIg) protein (Intragam, CSL, Parkville, Australia; 10 µg/ml in PBS) by overnight incubation at 4°C and washed four times with PBS to remove unbound antigen. Plates were incubated with serially diluted sera in blocking buffer (5% milk powder in PBS) overnight at 4°C. After washing  
5 times with PBS to remove unbound Ab, plates were incubated with  
30 peroxidase conjugated anti-mouse IgG, IgG1, IgG2a or IgG2b antibodies (Southern Biotechnology, Birmingham, AL, USA) diluted in blocking buffer. After washing five times with PBS, the amount of bound Ab was determined by addition of substrate solution (0.1 mg/ml 3,3',5,5'-tetra methylbenzidine (T2885, Sigma St. Louis, MO, USA) 0.03% H<sub>2</sub>O<sub>2</sub> in 0.1M Na acetate pH 6.0).  
35 The reaction was stopped with 1M H<sub>2</sub>SO<sub>4</sub> and the OD read at 450nm. Titres were defined as the highest dilution to reach an OD of 0.2.

To calibrate the IgG subclass ELISA, plates were coated with IgG1, IgG2a or IgG2b from mouse myelomas (10 µg/ml in 0.5 times PBS) overnight at 4°C, washed 3 times with PBS and then incubated with serially diluted anti-mouse IgG subclass HRP conjugated Ab. The dilution of each  
5 anti-mouse subclass Ab which gave identical absorbances in the ELISA were used subsequently.

### Results and Discussion

10 Expression plasmids were constructed to produce secreted forms of the human IgG1 heavy chain alone (pRep10::CD5L-hIg) or fused with CTLA4 (pRep7::mCTLA4-hIg) or L-selectin (pRep10::hLSEL-hIg). Cells transfected with these plasmids secreted the three molecules as disulphide linked dimers of expected size (Fig. 1). Like others (1) we were unable to detect *in vivo* protein expression by western blotting of muscle homogenates and or  
15 of protein A purified material from sera of B-cell deficient immunized mice (data not shown). However, the ability to detect immune responses in immunized mice is indicative of *in vivo* expression. No immune responses to human Ig were detected in unimmunised or mice receiving vector only (data not shown). However, mice immunized with pRep10::CD5L-hIg, pRep10::hL-SEL-hIg or pRep7::mCTLA4-hIg had markedly different responses (Fig. 2). Responses in pRep7::mCTLA4-hIg immunized mice were more rapid and of greater magnitude at all three time points: 2, 4 and 8 weeks (Fig. 2). At 4 weeks both the pRep7::mCTLA4-hIg and  
20 pRep10::hLSEL-hIg immunized mice had 1000 and 100 fold higher IgG responses than pRep10::CD5L-hIg controls respectively. The differences observed were not attributable to any adjuvant effects of endotoxin, because Triton X-114 was used to remove endotoxin (8) so that the levels were <10IU/mg plasmid DNA. Similar results have been achieved in 3  
25 experiments using BALB/c and CBA mice (data not shown).

The response in all mice to pRep10::CD5L-hIg was dominated by IgG2a (Fig. 3), which mimics a viral infection, and has been reported for other antigens after DNA immunisation (9, 10). The IgG subclass response in pRep10::hLSEL-hIg immunized mice was similar (although greater) to  
35 pRep10::CD5L-hIg controls whereas the pRep7::mCTLA4-hIg response was deviated to an IgG1 dominance (Fig. 3B). The possibility that the differences

in Ab responses was due to dose was unlikely since all constructs were made with identical plasmid backbone and mice immunized with soluble CTLA4Ig protein (Fig. 4) had higher Ab responses than those receiving an equivalent dose of hIg. Also, to determine if the IgG1 dominance of the response to pRep7::mCTLA4-hIg was due to dose we immunized mice with different amounts of pRep7::mCTLA4-hIg so that mice with total IgG antibody levels could be compared to that of pRep10::hLSEL-hIg (Figs. 2 and 3). The IgG1 predominance was found at all doses of pRep::mCTLA4-hIg (Fig. 5).

Work with CTLA4 has demonstrated it can bind to B-7 and block co-stimulation which reduces the response to other immunogens (11). A non-specific immunomodulatory effect of CTLA4 was unlikely for several reasons. Firstly, CTLA4Ig protein at least in high doses (and hence B-7 is blocked) has been ascribed immunosuppressive properties not immunostimulating ones (11) as we found for DNA and protein immunisations. Furthermore, mice co-injected with CTLA4Ig and DNA encoding ovalbumin (pCI-OVA) had similar ovalbumin specific IgG and IgG subclass titres to control mice (Fig. 6) indicating that there was not any immunosuppressive effect of CTLA4.

## **Example 2**

### **Use of targeting ligand to augment T cell proliferative responses and requirement for dimerisation**

#### *Introduction*

In Example 1 there is a demonstration that Ab levels to a model DNA vaccine could be enhanced when antigen was fused with the targeting ligands CTLA4 or L-selectin.

The hIg component would ensure dimerisation which we thought would be favourable because in general, binding of ligands to receptors is stronger when dimers are used. However, it was unclear in this system if dimerisation of the antigen targeting ligand fusion proteins was necessary for increased immune responses. To determine if the enhanced Ab response generated by antigen targeting vectors encoding proteins was dependent upon dimer formation, Ab responses were compared to immunisation with plasmid encoding monomeric antigen targeting ligand fusion proteins. The

hIg component of the vectors was replaced with coding sequence for another model antigen that would not form dimers (ovalbumin; OVA).

### *Materials and Methods*

5

Female mice aged 6 to 8 weeks were used in all experiments and maintained in SPF conditions.

After PCR amplification to include an Mlu I restriction enzyme recognition sequence, the OVA cDNA (bp 470-1170) was inserted behind the human immunoglobulin Fc (hIg) gene via a 4 amino acid glycine linker at the Nsi I site. These vectors would form dimers due to the interchain disulfide bonds of hIg and are represented by an hIg-OVA suffix. A targeting vector that would not form dimers was obtained by direct fusion of the cDNA from OVA to the cDNA of CTLA4 (pCI::mCTLA4-OVA) or to the leader sequence of CD5 as a control (pCI::CD5L-OVA). After PCR amplification to include Hind III and Nsi I restriction sites the entire hIg component of pCI::mCTLA4-hIg-OVA was replaced with the human IgG3 hinge region (a gift from Dr Y Akahori, Japan) to form pCI::mCTLA4-g3h-OVA. Plasmids for injection were prepared from *E. coli* with endofree QIAGEN maxi kits according to the manufacturer's instructions and stored at -20°C in normal saline until injected. Mice received 50 µg of plasmid DNA in 100 µl normal saline i.m. in both quadriceps at day 0 of each experiment.

The proliferation of  $2 \times 10^5$  splenocytes was determined by a standard 5 day <sup>3</sup>H-thymidine uptake protocol at 6 weeks post initial immunisation. The mean stimulation index was calculated as the cpm with antigen / cpm splenocytes alone.

Microtitre plates (NUNC, Maxisorb) were coated with OVA protein (A-5503, Sigma, St. Louis, MO; 10 µg/ml in PBS) by overnight incubation at 4°C and washed four times with PBS to remove unbound antigen. Plates were incubated with serially diluted sera in blocking buffer (1% casein in PBS) overnight at 4°C. After washing 5 times with PBS to remove unbound Ab, plates were incubated with peroxidase conjugated anti-mouse IgG (Southern Biotechnology, Birmingham, AL) diluted in blocking buffer. After washing five times with PBS, the amount of bound Ab was determined by addition of tetramethylbenzidine substrate solution. The reaction was

stopped with 1M H<sub>2</sub>SO<sub>4</sub> and the OD read at 450nm. Titres were defined as the highest dilution to reach an OD of 0.2.

### *Results and Discussion*

5

The proliferation splenocytes was determined by a standard 5 day 3H-thymidine uptake protocol at 6 weeks post initial immunisation (Fig. 7). The stimulation index was calculated as the cpm with antigen / cpm splenocytes alone. The mean  $\pm$ SD from 3 mice in each group is shown after  
10 incubation with three different antigen concentrations. Mice immunized with the DNA constructs pCI::mCTLA4-hIg and pCI::Lsel-hIg had 8 and 3 fold higher T cell proliferative responses than controls (pCI::CD5L-hIg) respectively. This data suggested that the targeting of antigen was having an enhancing effect on T cell activation.

15

Groups of 8 mice were immunized with DNAs expressing the monomeric targeting vector pCI::mCTLA4-OVA, the monomeric control pCI::CD5L-OVA, or the dimeric vectors pCI::CD5L-hIg-OVA (control), pCI::Lsel-hIg-OVA or pCI::CTLA4-hIg-OVA on day 0 and bled 2 and 4 weeks post immunisation. The OVA specific IgG levels were determined by ELISA.  
20 The results obtained at 2 and 4 weeks post immunisation are illustrated in Fig. 8 (2 weeks; hatched columns, 4 weeks; solid columns). There was no difference in Ab levels at 2 or 4 weeks between the mice immunized with pCI::CD5L-OVA or pCI::mCTLA4-OVA monomeric DNA vectors. The highest Ab responses were obtained with the pCI::mCTLA4-hIg-OVA vector,  
25 which forms dimers, compared to the monomeric (pCI::CD5L-OVA) or dimeric (pCI::CD5L-hIg-OVA) controls.

Surprisingly, the pCI::Lsel-hIg-OVA immunized mice had the poorest responses at both time points. This data is in contrast to the enhanced responses to hIg when fused with L-selectin alone. The observation that the  
30 responses obtained with pCI::Lsel-hIg-OVA were similar in magnitude to those obtained with the monomeric antigen fusions suggests that the fusion of OVA (or other antigens) to Lsel-hIg may interfere with the efficiency of binding of L-selectin to its ligand (e.g. by interfering with dimerisation, by allosteric effects or by conformational changes to L-selectin). Alternative  
35 ways of fusion should be investigated.

Overall, these results suggest that for effective antigen targeting the inclusion of a molecule such as hIg that facilitates dimerisation is essential unless the antigen itself facilitates dimerisation or multimerisation. This data was obtained using the hinge, CH2 and CH3 domains of human IgG1.

5 The dimerisation of hIg is facilitated by disulfide bonds between cysteine residues in the hinge domains. To determine if another molecule that would also facilitate dimerisation could replace the hIg component, the hinge region of human IgG3 was used to link mCTLA4 with OVA. Groups of 8 mice were immunized with DNAs expressing the targeting vectors

10 pCI::mCTLA4-hIg-OVA or pCI::mCTLA4-g3h-OVA. At 2 weeks post immunisation sera was collected and shown to contain similar levels of anti-OVA antibodies (Fig. 9). Therefore, this suggests that it may be possible to reduce the hIg component of the antigen targeting vectors to a hinge region alone or replace the hIgG1 component with another immunoglobulin

15 hinge region, another molecule or part thereof such as the hIgG3 hinge to facilitate dimerisation. This would be of particular applicability when the targeting ligand is L-selectin or another molecule that does not dimerise or is structurally compromised by fusion of antigen via hIg.

20 Example 1 demonstrated an increased immune responses to hIg after DNA and protein immunisation was obtained with targeting ligand-hIg fusions. The following Examples were conducted to determine if antigens other than hIg could be used for increased immune responses. These data were obtained by the addition of antigens to the C-terminus of hIg which

25 could facilitate dimer formation as was found with hIg alone. A gly-gly-gly-gly-thr spacer was introduced between hIg and the antigens. Whilst these constructs have been used it will be appreciated that responses may be improved by routine optimisation. This optimisation may involve modification of the constructs as envisaged within the present invention eg

30 different targeting molecules, different sequences which facilitate multimerisation, different linkers etc.

**EXAMPLE 3****Use of CTLA4 to accelerate immune responses against the host protective antigen of *Taenia ovis* known as 45W****5   Introduction**

The 45W antigen is a putative membrane glycoprotein present in, or underlying the tegument of, the *Taenia ovis* oncosphere. *T. ovis* is a pathogen of sheep which causes commercial losses of mutton and wool in New Zealand and other important sheep growing countries. Early immunisation studies using 45W protein partially purified from *T. ovis* revealed that it was a promising vaccine antigen. Subsequent field trials using recombinant forms of 45W, expressed in *Escherichia coli*, as a vaccine reported very high levels (about 95%) of protection<sup>13</sup>. The 45W antigen was used as a DNA vaccine in sheep and low levels of antibody, measured using a recombinant form of 45W, was observed<sup>14</sup>.

**Materials and Methods**

20       Plasmids containing the CMV promoter and the genes encoding CTLA4, the Fc portion of human immunoglobulin (hIg) and the CD5 signal peptide were described above. The gene encoding 45W was obtained from Dr. Marshall Lightowlers (Dept. Veterinary Science, University of Melbourne).

25       Inbred Balb/c mice of 6-8 weeks of age were obtained from the Dept. Microbiology and Immunology Animal House, University of Melbourne.

Standard DNA manipulation and CsCl purification techniques were used. The gene encoding 45W was ligated into two DNA vaccines. Construct pCI::mCTLA4-hIg-45W expressed a fusion protein which comprised the CTLA4 signal peptide, mouse CTLA4 ectodomain, hIg and the 45W antigen. Construct pCI::CD5L-hIg-45W expressed a fusion protein which contained the signal peptide from CD5, hIg and the 45W antigen.

30       DNA (100µg) was injected into the quadriceps of mice on days 0 and day 28. Sera was obtained at appropriate intervals post vaccination and analysed for total antibodies specific for recombinant 45W antigen in a

titration ELISA<sup>15</sup> using horseradish peroxidase conjugated anti-mouse immunoglobulins.

Purified recombinant 45W(His)<sub>6</sub> was obtained from *E. coli* according to Rothel *et al.*<sup>14</sup> using a polyhistidine 'tag' and nickel affinity  
5 chromatography.

### Results

Mice were immunised with the DNA vaccines pCI::mCTLA4-hIg-45W,  
10 or pCI::CD5L-hIg-45W (Figure 10). Mice received 100µg of DNA on days 0 and 28 and were bled at weekly intervals. Mice receiving the DNA vaccine which expressed CTLA4 fused to the hIg/45W vaccine developed a more rapid antibody response than the mice which received a similar plasmid vaccine construct ie. pCI::CD5L-hIg-45W which did not contain the CTLA4  
15 gene. The mice receiving the vaccine with CTLA4 produced serum antibodies of high titre (ie. ≥10,000) on days 7, 14 and 28. In comparison, mice which received the construct lacking CTLA4 did not produce high titre antibodies (ie. titre ≥10,000) until after the second immunisation on day 28. All mice (ie. 5/5) which received the DNA vaccine containing CTLA4  
20 produced 45W-specific antibodies by 7 days post immunisation whereas only 1/5 animals which received the equivalent DNA vaccine lacking CTLA4 produced antibodies at day 7 post immunisation. The data was analysed using Student's t-test.

A second trial was undertaken where mice received either 20µg of  
25 purified recombinant 45W(His)<sub>6</sub> protein in Complete Freund's Adjuvant, or the CTLA4 DNA vaccine (ie. pCI::mCTLA4-hIg-45)(Figure 11). The serum antibody response was examined on days 0, 2, 5, 8, 14 and 28. The serum antibody response specific for 45W was higher at day 8 in DNA vaccinated mice than in mice which received the 45W protein vaccine.

30

### Discussion

The murine serum antibody response to 45W DNA vaccination was accelerated by fusion of CTLA4 to the hIg-45W fusion protein. The antibody  
35 response to 45W correlates with protection in sheep against *T. ovis* disease. Addition of CTLA4 led to a more rapid high titre response, with a shorter



unprotected period following immunisation. The effect of CTLA4 on the magnitude of the anti-45W response was not as dramatic as the effect on human Ig described above. This may have been due to the conformational restraints from the fusion of the various molecules or some inherent property of the 45W antigen. Furthermore, the immunisation protocol employed in this Example differed from Example 1 in that boosting occurred at 4 rather than two weeks. Due to the more rapid kinetics of the response via CTLA4 targeting boosting may not have been optimum and thus the magnitude was not effected.

#### Example 4

**Use of CTLA4 with AMA1 to protect against *Plasmodium chabaudi adami* in mice**

#### Introduction

AMA1<sup>16</sup> is a candidate vaccine antigen against malaria. We have evidence that domain3 of AMA1 folds independently and as such may be a good candidate in producing a fusion protein with hIg. However, although AMA1 has been shown to confer protection in mouse malaria<sup>17</sup>, we are unaware of any work that has shown domain3 to be protective.

#### Materials and Methods

Plasmids containing the CMV promoter and the genes encoding CTLA4, the Fc portion of human immunoglobulin (hIg) and the CD5 signal peptide were described above. Domain 3 of AMA-1 from the *Plasmodium chabaudi adami* DS strain<sup>16</sup> was fused to CTLA4Ig and CD5LIg (pCI::mCTLA4-hIg-AMA and pCI::CD5L-hIg-AMA). The plasmid pCI::mCTLA4-hIg was used as a negative control.

Inbred female Balb/c mice of 6-8 weeks of age were used.

DNA (100ug) was injected into the quadriceps of mice on day 0 only. Mice were challenged with *Plasmodium chabaudi adami* DS and the number of deaths recorded.

Antibody titres were measured by ELISA using refolded *E.coli* expressed entire ectodomain of AMA1<sup>17</sup>. The titres were expressed as the log of the reciprocal of the last serum dilution to give an OD >0.1.

## 5 Results

In the first trial, there were 8 mice per group. A single immunisation with the DNA vaccine pCI::mCTLA4-hIg-AMA afforded partial protection against an intraperitoneal challenge of 100,000 parasites (Figure 12).

10 Challenge was performed 14 days after immunisation. This was significant (log rank test;  $p < 0.05$ ) from the control pCI::mCTLA4-hIg group. There was a clear indication that the CTLA4 conferred better protection than the pCI::CD5L-hIg-AMA group, although this did not reach statistical significance. The antibody titres (Figure 13) show that the CTLA4 targeting  
15 ligand enhances the antibody response to AMA1 ( $p < 0.005$ ).

A second trial was undertaken with larger group (16/group) and with an intravenous challenge of 10,000 parasites. No protection was seen in this second trial.

## 20 Discussion

In the first trial, CTLA4 conferred some protection against malaria by domain3 of antigen AMA1. This was not found in the second trial. We do not know why there was a difference between the two trials. Because there  
25 is not a full set of antibody data for comparison, we do not know whether the level of antibody achieved was sufficient in the mice that died in trial two, or whether the effect was due the different route of challenge. We also do not know how effective CTLA4IgAMA may be when booster doses are given.

## 30 Example 5

### Use of CTLA4 in influenza infection in mice

#### Introduction

35 As an additional model for testing protective efficacy we have used influenza infection of the murine respiratory tract. The influenza

haemagglutinin (HA) gene was cloned behind targeting molecules and the resulting DNA vaccines examined for their ability to generate higher anti-viral antibody titres and afford greater protection against live viral challenge compared to control vaccines not expressing the targeting molecule.

### *Materials and Methods*

#### Virus

The type A influenza virus used in this study was PR8 = A/Puerto Rico/8/34 (H1N1). Virus was grown in the allantoic cavity of 10-day embryonated hens' eggs for 2 days at 35°C. The allantoic fluid was collected and clarified by centrifugation (2000g, 15 mins, 4°C). Aliquots of allantoic fluid containing infectious virus were stored at -70°C and used for immunisation and challenge of mice. Purified PR8 virus used in ELISA assays was obtained as zonally purified stocks from CSL Ltd, Parkville, Victoria, Australia. The haemagglutination assay<sup>18</sup> was used to quantitate virus and titres are expressed in haemagglutinating units (HAU) per ml.

#### Immunisation

Groups of 10 BALB/c mice were immunised intramuscularly (i.m.) under anaesthesia on day 0 with 0.1 ml of DNA vaccine containing 50µg of plasmid. The constructs used for immunisation were pCI::CD5L-hIg-HA, pCI::mCTLA4-hIg-HA, which were based on PR8 HA lacking the signal and transmembrane sequences, and pCI::CD5L-hIg-SIINFELK (expressing an 8 amino acid sequence from chicken ovalbumin) as a negative control. As a positive control, a group of 10 BALB/c mice were infected intranasally (i.n.) with 50 plaque forming units (pfu) of infectious PR8 virus and another group immunised subcutaneously with 1µg of β-propiolactone (BPL)-inactivated and sodium taurodeoxycholate-disrupted PR8 virus (split virus). Serum samples were collected from all mice on days 7, 14 and 54 and mice were then challenged on day 65.

#### Intranasal challenge of mice and preparation of mouse lung extracts

Penthrane anaesthetised mice were challenged with 50 pfu of infectious PR8 influenza virus i.n.. Each mouse received 50 µl of virus in the

form of allantoic fluid diluted in phosphate buffered saline (PBS). Five days after challenge, mice were killed by cervical dislocation and lungs were removed and transferred aseptically to bottles containing 1.5 ml Hanks Balanced Salt Solution (HBSS), supplemented with 100 U of penicillin per ml, 100  $\mu$ g of streptomycin per ml and 30  $\mu$ g of gentamicin per ml. Lung homogenates were prepared using a tissue homogeniser. Each lung suspension was then centrifuged at 300 x g for 5 minutes and the supernatants were removed, aliquoted and stored at -70°C prior to assay for infectious virus.

10

#### Enzyme-linked immunosorbent assay

The enzyme-linked immunosorbent assay (ELISA) was performed as previously described by Jackson *et al.*<sup>19</sup> using 96-well polyvinyl microtitre trays (Dynatech, Australia) coated with a solution containing 50 HAU of purified PR8 virus per well. Antibody titres are expressed as the reciprocal of the antibody dilution giving an absorbance of 0.2 units.

15

#### Plaque assay for infectious virus

Virus titres were determined by plaque assay on monolayers of Madin-Darby canine kidney (MDCK) cells in 35 mm petri dishes (Nunc, Roskilde, Denmark). The culture medium was RPMI-1640 supplemented with 2 mM glutamine, 2 mM sodium pyruvate, 100 U of penicillin per ml, 100  $\mu$ g of streptomycin per ml, 30  $\mu$ g of gentamicin per ml and 10% (vol/vol) foetal calf serum (heat inactivated at 56°C for 30 min). Monolayers were washed with serum-free RPMI-1640 containing antibiotics and inoculated in duplicate with 100  $\mu$ l of dilutions of lung homogenates in the same medium. After allowing 45 minutes in a humidified incubator (37°C, 5% CO<sub>2</sub>) for virus adsorption, 3 ml of agarose overlay medium at 45°C was added. Incubation was continued for a further 3 days and plaques counted. The agarose overlay medium was Leibovitz L-15 medium pH 6.8 (Gibco Laboratories, U.S.A.) supplemented with 100 U penicillin per ml, 100  $\mu$ g of streptomycin per ml, 0.01 M HEPES buffer pH 6.8 (Calbiochem, Australia), 0.1% trypsin-TPCK (Worthington, Biological Systems Inc., U.S.A.) and 0.9% agarose (ICN Biomedicals Sydney, Australia).

35

### Statistical analysis

The data were analysed using the nonparametric Mann-Whitney U test which compares two sets of unpaired samples. The null hypothesis is that the two population medians are equal and the resultant P value for particular comparisons is given.

### *Results and Discussion*

#### Serum antibody responses of mice

Sera collected from mice immunised with the DNA constructs, split PR8 virus in PBS, or infectious PR8 virus were assayed for anti-viral antibody by ELISA. On day 7 after priming, only mice immunised with infectious PR8 virus exhibited anti-viral antibody titres significantly higher than the background titres detected in mice given the control DNA construct pCI::CD5L-hIg-SIINFELK (p=0.0002). However by day 14, in addition to the high antiviral antibody titres detected in the virus infected mice, antibody titres of mice immunised with the pCI::mCTLA4-hIg-HA construct were significantly higher than those of mice given the control DNA constructs pCI::CD5L-hIg-HA (p=0.0003) or pCI::CD5L-hIg-SIINFELK (p=0.0004) (Fig. 14). Furthermore, mice immunised with the pCI::mCTLA4-hIg-HA construct had comparable levels of antiviral antibody to mice given the split virus vaccine (p=0.97). The antiviral antibody titres of sera collected on day 54 post-priming were also determined (Fig 15). Overall, the day 54 titres were similar to those measured in sera collected on day 14, and the level of antibody in the day 54 sera of mice given the pCI::mCTLA4-hIg-HA construct remained significantly higher than that of mice given pCI::CD5L-hIg-HA (p=0.009) or pCI::CD5L-hIg-SIINFELK (p=0.0028), and comparable to split virus (p=0.85).

#### Ability of PR8 HA constructs to elicit protective immunity

Protection of vaccinated mice from influenza infection was assessed by examining the ability of mice to clear a challenge dose of virus from their lungs by five days post-infection. It should be noted that both antibody and cytotoxic T cell-mediated responses can lead to viral titre reduction within this 5 day interval. Mice were challenged on day 65 post-priming and the titre of virus in their lung was determined by a plaque assay. Figure 16

shows that all mice immunised with infectious virus were able to clear the challenge dose of virus. Of the mice given DNA constructs, the lung virus titres of mice immunised with the pCI::mCTLA4-hIg-HA construct were significantly lower than those of mice immunised with either

- 5 pCI::CD5L-hIg-HA ( $p=0.0004$ ) or pCI::CD5L-hIg-SIINFELK ( $p=0.0002$ ). Also the level of clearance observed in the pCI::mCTLA4-hIg-HA construct-immunised mice was almost as good as that seen in mice given the split virus vaccine.

## 10 *Conclusions*

- pCI::CTLA4-hIg-HA conferred higher antibody levels and better protection against challenge compared with the control vector pCI::CD5L-hIg-HA demonstrating the immune enhancing effect of the  
15 incorporation of the targeting molecule.

### **Example 5**

**Use of CTLA4 in *Corynebacterium pseudotuberculosis* in sheep.**

## 20 *Introduction*

- Corynebacterium pseudotuberculosis* is the causative agent of caseous lymphadenitis (CLA) in sheep. Established infection by these bacteria leads to the formation of abscesses in the lymph nodes, especially the draining  
25 lymph node of the site of infection. Phospholipase D (PLD) has been characterised as a virulence factor and a protective antigen for CLA. Indeed formalin-treated PLD<sup>20</sup> or genetically toxoided PLD ( $\Delta$ PLD<sup>22</sup>) has been shown to protect sheep from CLA.

- We have used the genetically toxoided PLD as the basis for our DNA  
30 vaccination approach and investigated whether the addition of bovine (b)CTLA4-hIg or hIg alone to the  $\Delta$ PLD construct enhanced the immune response to PLD and to hIg.

### *Materials and methods.*

#### DNA constructs

Using the known sequence of bCTLA4 (GenBank accession number X15070), the bCTLA4 gene was isolated from bovine peripheral blood mononuclear cells. A PCR product of bCTLA-4 (729 bp) was cloned into the Zeroblunt TM cloning vector according to the manufacturer's instructions (Invitrogen) and sequenced using the Applied Biosystems automated sequencer. The sequence of bCTLA4 was found to be identical to the published sequence.

The following constructs were generated in the pCI vector for DNA immunisation:

- pCI::bCTLA4-hIg-APLD
- pCI::APLD
- pCI::bCTLA4-hIg
- pCI::CD5L-hIg-APLD\*

\* CD5L refers to the leader sequence of the CD5 molecule allowing the huIg-APLD protein to be secreted.

#### 20 Experimental animals and immunisation regimen

Cross-bred ewes aged 12 weeks were used in the challenge trial. 10 animals were allocated randomly to each group. Animals were pre-screened for the presence of antibodies to PLD and to *Corynebacterium pseudotuberculosis* lysate. Positive animals were excluded from the trial.

25 Shearing, vaccination and tail docking of animals was avoided to minimise risk of infection with *Corynebacterium pseudotuberculosis*.

Animals were injected intra-muscularly with 500 µg LPS free pCI plasmid DNA (coding for either pCI::bCTLA4-hIg-APLD, pCI::APLD, pCI::bCTLA4-huIg or pCI::CD5L-huIg-APLD) in 5 ml of PBS. Control animals received either Glanvac or were left un-immunised. All animals received the same vaccine, at the same dose, 4 weeks later.

#### Challenge

Bacterial cultures of wild type *Corynebacterium pseudotuberculosis* were grown at 37° C in Brain heart infusion broth (Difco Laboratories) containing 0.1% Tween 80 (BHI).

All sheep were challenged 6 weeks after primary immunisation using a 1 ml dose of  $10^6$  CFU of *Corynebacterium pseudotuberculosis* injected just above the coronet of the right hind lateral claw.

## 5 Immunological assays

Sera were collected from the sheep at weekly intervals and assayed for the presence of antibodies to genetically detoxified PLD ( $\Delta$ PLD) and hIg using an ELISA. Plates were coated with 1/50 of culture supernatant from  $\Delta$ PLD expressing *Corynebacterium pseudotuberculosis* or 5 g/ml hIg protein.  
10 The sera were diluted in two fold steps starting at 1/100 and 1/10 for the detection of anti- $\Delta$ PLD and anti-hIg antibodies respectively. Titres were calculated by linear regression on a double logarithmic scale in the linear part of the graph. The titre was defined as the dilution, which resulted in an O.D. 0.3 in the ELISA.

15 T cell proliferation assays were performed in triplicates using 2 concentrations of  $\Delta$ PLD (1/50 and 1/250) or hIg (5 g/ml and 25 g/ml) as an antigen. PBMC were purified by ficoll gradient and cultured *in vitro* for 3 days. The cultures were pulsed with 3H-methyl-thymidine for 18 hours before being harvested on glass fibre filters and radioactive incorporation  
20 assessed. The results are presented as stimulation indices (i.e. ratio between counts obtained with antigen over counts obtained without antigen).

Statistical analysis was performed using the Systat program. The non-parametric Mann-Whitney U test was used to calculate significance. p  
25 values below 0.05 were considered significant.

## *Results*

### Anti-hIg antibody levels

30 The antibody titres to human immunoglobulin (hIg) reflect the immune response to the DNA vaccination against the hIg part of the fusion protein in the case of bCTLA4-hIg- $\Delta$ PLD, CD5L-hIg- $\Delta$ PLD and bCTLA4-hIg. By comparing the response to hIg from the animals injected with pCI::bCTLA4-hIg- $\Delta$ PLD to these injected with pCI::CD5L-hIg- $\Delta$ PLD it is  
35 possible to specifically evaluate the effect of bCTLA4 targeting on the immunogenicity of hIg. Results shown in Fig 17 indicate that the antibody



response to hIg in animals injected with pCI::bCTLA4-hIg-ΔPLD (filled squares) is both earlier and stronger than the anti-hIg response induced in animals immunised with pCI::CD5L-hIg-ΔPLD (closed circles). The Mann-Whitney U test indicates a statistically significant difference for weeks 3 and 4. Corroborating these results the anti-hIg response in the group injected with pCI::bCTLA4-hIg (closed triangles) is also earlier and stronger than the response in animals injected with pCI::CD5L-hIg-ΔPLD.

#### Anti-ΔPLD antibody levels

Immunisation with the detoxified-PLD protein antigen (Glan-Vac) resulted in little or no detectable antibodies during the first 7 weeks after immunisation. Two weeks after challenge antibody levels increased dramatically. This is consistent with previously reported results<sup>21</sup>

All groups immunised with pCI encoding the ΔPLD antigen either alone or as a fusion protein with bCTLA4-hIg or with CD5L-hIg, resulted in similar kinetics of antibody production. Indeed, no significant anti-ΔPLD antibody levels were detected until 2 weeks post-challenge (i.e. week 8). At each time point there was no significant difference between the level of antibodies induced by the different pCI constructs, indicating that all constructs have a similar ability to induce immune memory to ΔPLD. However, this result is not surprising in light of the fact that detoxified-PLD is not a classical antigen in that two doses of the protein antigen (Glan-Vac group) failed to induce substantial antibody levels. This result has also been reported by others<sup>22</sup>. Thus detoxified-PLD seems to result in the induction of immune memory without induction of high antibody titres. This immune memory is then activated during the early stage of the challenge by PLD expressed by *Corynebacterium pseudotuberculosis*. It is interesting to note that ΔPLD expressed in eukaryotic cells (COSm6 cells) has a slightly larger size compared to ΔPLD expressed in *Corynebacterium pseudotuberculosis* (Fig 18). This difference can be accounted for by the possible glycosylation of ΔPLD in eukaryotic cells. As in the case with anti-hIg antibody levels it is noted that sheep, in contrast to mice, do not produce antibodies over prolonged periods of time following DNA vaccination.

### T cell responses to $\Delta$ PLD and hIg.

T cell responses to  $\Delta$ PLD and hIg were analysed at 3 weeks, 6 weeks and 9 weeks. No significant antigen specific proliferation, to these two antigens could be demonstrated in peripheral blood mononuclear cells (PBMC) at any time point. This is most likely due to technical difficulties since the kinetics of the anti  $\Delta$ PLD response indicate the likely presence of memory T cells in the vaccinated animals.

### Anti- $\Delta$ PLD response subsequent to challenge with virulent

#### *C. pseudotuberculosis*.

Challenge was performed at 6 weeks post-immunisation (i.e. two weeks post-booster immunisation). Observation of the site of inoculation at week 10 did not reveal any correlation with immunisation regime. Except in the case of the unvaccinated control and pCI::bCTLA4-hIg immunised animals, the antibody response to  $\Delta$ PLD increased two weeks post-challenge (week 8). This indicates that the immune memory induced by the immunisation with DNA can be boosted with  $\Delta$ PLD produced by *Corynebacterium pseudotuberculosis*. This indicates that although  $\Delta$ PLD produced by DNA vaccination is most likely glycosylated there is still cross-reaction with bacterial wild-type PLD.

In the un-immunised control animals the level of anti- $\Delta$ PLD antibodies remains low until 3 to 4 weeks post-challenge (week 9). This kinetics of antibody appearance has been described previously<sup>22</sup>. Interestingly the antibody levels in the animals primed with  $\Delta$ PLD by DNA vaccination or detoxified-PLD by Glan-Vac injection, diminished after week 8 suggesting that the PLD antigen is no longer boosting the immune response. This may be due to a diminished level of PLD secretion due to the animals clearing *Corynebacterium pseudotuberculosis*.

#### Protection from challenge with virulent *Corynebacterium pseudotuberculosis*.

At week 12 post vaccination (6 weeks post challenge) necropsy of all animals was performed to evaluate the protective efficacy of the immunisation protocol. Both left and right popliteal, inguinal and prefemoral lymph nodes were dissected and visually assessed for the characteristic abscesses induced by *Corynebacterium pseudotuberculosis*. The lungs were palpated to detect abscesses and no lung abscesses were

found in any of the animals. Protection was defined as the absence of the characteristic *Corynebacterium pseudotuberculosis* abscesses in any of the lymph nodes. In two sheep small dry lesions were observed in the draining popliteal lymph node, clearly distinct from the abscesses in the other  
5 animals. These lesions were most likely foci of *Corynebacterium pseudotuberculosis* which were regressing in the face of an effective immune response and these animals were also scored as "protected". From Fig 19 it can be seen that while about 10 % of the unvaccinated animals did not develop lesions, 90 % were protected by vaccination with Glan-Vac. Only 1  
10 animal out of 10 injected with pCI::CTLA4-hIg did not have abscesses in the lymph nodes. All animals vaccinated with DNA encoding for  $\Delta$ PLD (pCI::bCTLA4-hIg- $\Delta$ PLD, pCI:: $\Delta$ PLD and pCI::CD5L-hIg- $\Delta$ PLD) were afforded some protection. The level of protection ranged from 40 to 70% with the highest degree of protection observed in the group injected with  
15 pCI::CTLA4-hIg- $\Delta$ PLD.

### Conclusion

This study has examined the ability of bCTLA4 to increase the  
20 immune response to antigens during DNA immunisation in sheep. bCTLA4 has the ability to accelerate and increase the immune response to hIg. Challenge with *Corynebacterium pseudotuberculosis* indicated that DNA vaccination could induce a protective immune response. When comparing the protection obtained with pCI::bCTLA4-hIg- $\Delta$ PLD and  
25 pCI::CD5L-hIg- $\Delta$ PLD a substantial difference was observed.

The protection induced by CD5L-hIg- $\Delta$ PLD is lower than the protection induced by  $\Delta$ PLD on its own. This difference may be due to the fact that the  $\Delta$ PLD molecule is much smaller than the bCD5L-hIg- $\Delta$ PLD and hence could be expressed in an acceptable conformation more easily. One  
30 could therefore expect that the bCTLA4-hIg- $\Delta$ PLD molecule which is even larger would be even more difficult to express. Hence the fact that the bCTLA4-hIg- $\Delta$ PLD molecule induced higher levels of protection indicates that the CTLA4 molecule effectively increases the immunogenicity of the fusion protein. It can be reasonably expected that by improving the level of  
35 expression and folding of the molecule even better protection could be

obtained. One way of achieving this would be to reduce the size of the hIg portion of the fusion protein.

#### Example 7

#### 5 Vaccination of C3H/He mice with DNA encoding the Parasite Surface Antigen 2 (PSA2) of *Leishmania major*.

##### *Introduction*

10 Protection against infection with this obligatory intracellular parasite is provided by CD4+ T cells of the macrophage activating, Th1 type. We have shown that injection of plasmid DNA encoding full length PSA2 induced significant protection against a challenge infection in C3H/He mice. This protection correlated with the induction of a very low, but consistent  
15 Th1 type of immune response, ie induction of T cells secreting interferon gamma, but no IL-4. Here we aim to examine the ability of CTLA4-Ig to improve the level of protection.

##### *Materials and methods*

20

PSA2 encoding residues 33-357 (missing the leader and gpi signal) was fused C-terminal to either pCI::CD5L-hIg or pCI::mCTLA4-hIg. DNA encoding a secreted form of PSA2 (residues 1-357) was also made (pCI::PSA2)

25

Groups of 8 mice were injected with 100 µg DNA in 100 µl phosphate buffered saline (PBS) intramuscularly twice at two week intervals. Two weeks after each injection the mice were bled and the serum tested for antibodies to PSA-2. Two weeks after the second injection the mice were infected intradermally with 100,000 promastigotes. The development of  
30 lesions at the site of infection was monitored weekly and scored according to size. Parasite burdens in the lymph nodes draining the lesion were determined by limiting dilution analysis at 7 weeks after challenge infection.

## Results

### Antibody production

Antibodies were measured only by ELISA OD at a single point. Two weeks after the first immunisation, 4 of 8 mice immunised with pCI::mCTLA4-hIg-PSA2 and 3 of 8 mice given pCI::CD5L-hIg-PSA2 produced significant antibody at a dilution of 1:500. However, after the second injection of DNA mice immunised with pCI::mCTLA4-hIg-PSA2, pCI::CD5L-hIg-PSA2 and our own secreted form of PSA-2 showed significant levels of antibody at this dilution. The PBS control had background antibody.

### Protection from infection

Mice immunised with DNA encoding pCI::CD5L-hIg-PSA2 and the controls PBS and vector DNA developed lesions at the site of infection 1 week after challenge. Mice immunised with pCI::mCTLA4-hIg-PSA2 or pCI::PSA2 developed lesions only 3 weeks after infection and the size of the lesions was smaller compared to the rest. Mice immunised with pCI::mCTLA4-hIg-PSA2 or pCI::PSA2 also had the smallest number of mice which developed lesions with only 5 of 8 mice showing any lesions at the peak of the disease curve (Fig 20). Notably, pCI::mCTLA4-hIg-PSA2 conferred better protection than pCI::CD5L-hIg-PSA2 ( $p=.0001$ ; log rank test).

### **Summary**

The ability to overcome the problem of low or absent responsiveness in DNA immunisation by antigen targeting enhances the potential of genetic vaccines. The present inventors also show that intramuscular injection of DNA can also be employed to deviate immune responses to the same antigen allowing for the development of vaccines in which the response most likely to confer protection can be generated.

Intramuscular injection of expression plasmids shows great potential for genetic vaccination. The present inventors have shown that fusion proteins consisting of antigen and cell surface receptor ligands could deliver antigen to sites of immune induction which enhance the immune response and possibly the efficacy of genetic vaccines. As set out above mice were

immunized with plasmids encoding Fc fragment of human IgG1 as antigen. This Ig fragment was fused with CTLA4 (CTLA4Ig) for delivery to antigen presenting cells (APC) expressing B-7, or with L-selectin (L-SELIg) for delivery to high endothelial venule cells of lymph nodes. L-selectin binds  
5 CD34 and MadCAM-1 and so could target any lymphoid organ with these receptors (12). Enhanced antibody responses were shown in both the CTLA4Ig and L-SELIg immunized mice, 1000 and 100 fold respectively at 4 weeks. Moreover the response after CTLA4Ig immunisation was the most rapid. Immune deviation from an IgG2a to an IgG1 dominated response  
10 occurred in CTLA4Ig immunized mice and allows for the development of genetic vaccines in which the response most likely to confer protection can be generated.

It will be appreciated by persons skilled in the art that numerous  
15 variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

### References

1. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. De Witt, A. Friedman, L. A.
- 5 Hawe, K. R. Laender, D. Martinez, H. C. Perry, J. W. Shiver, D. L. Montgomery, and M. A. Liu. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. *Science* 259:1745.
2. Wolff, J. A., P. Williams, G. Acsadi, S. Jiao, A. Jani, and W. Chong. 1991. Conditions affecting direct gene transfer into rodent muscle in vivo.
- 10 *Biotechniques* 11:474.
3. Hohlfeld, R., and A. G. Engel. 1994. The immunobiology of muscle. *Immunol. Today* 15:269.
4. Pardoll, D. M., and A. M. Beckerleg. 1995. Exposing the immunology of naked DNA vaccines. *Immunity* 3:165.
- 15 5. Raz, E., D. A. Carson, S. E. Parker, T. B. Parr, A. M. Abai, G. Aichinger, S. H. Gromkowski, M. Singh, D. Lew, M. A. Yankauckas, S. M. Baird and G. H. Rhodes. 1994. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. *Proc. Natl. Acad. Sci.* 91:9519.
- 20 6. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson and L. D. Falo, Jr. 1996. DNA-based immunization by *in vivo* transfection of dendritic cells. *Nature Med.* 2: 1122.
7. In *Molecular cloning: A laboratory manual*. 2nd ed. 1989. J. Sambrook, E. F. Fritsch, and T. Maniatis, eds. Cold Spring Harbor Press, Cold Spring
- 25 Harbor, NY, p1.38.
8. Aida, Y., and M. J. Pabst. 1990. Removal of endotoxin from protein solutions by phase separation using Triton X-114. *J. Immunol. Methods.* 132:191.
9. Major M. E., L. Vitvitski, M. A. Mink, M. Schleef, R. G. Whalen, C. Trepo and G. Inchauspe. 1995. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. *J. Virol* 69:5798.
- 30 10. Manickan, E., R. J. Rouse, Z. Yu, W. S. Wire, and B. T. Rouse. 1995. Genetic immunization against herpes simplex virus. Protection is mediated
- 35 by CD4+ T lymphocytes. *J. Immunol.* 155:259.

11. Linsley P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. *Science* 257:792.
12. Varki A. 1994. Selectin Ligands. *PNAS* 91:7390.
- 5 13. Rickard MD (1991). Cestode vaccines. *Southeast Asian J Trop Med Public Health* 22 Suppl:287-290.
14. Rothel JS, Waterkeyn JG, Strugnell RA, Wood PR, Seow HF, Vadolas J, Lightowlers MW. (1997) Nucleic acid vaccination of sheep: Use in combination with a conventional adjuvanted vaccine against *Taenia ovis*.
- 10 Immunol Cell Biol 75:41-46.
15. Rothel JS, Lightowlers MW, Seow HF, Wood PR, Rothel LJ, Heath DD, Harrison GB. (1996) Immune responses associated with protection in sheep vaccinated with a recombinant antigen from *Taenia ovis*. *Parasite Immunol* 18:201-208.
- 15 16. Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ, Anders RF (1996) The disulfide bond structure of Plasmodium apical membrane antigen-1. *J Biol Chem* 271:29446-52.
17. Crewther PE, Matthew ML, Flegg RH, Anders RF (1996) Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi
- 20 involve recognition of strain-specific epitopes. *Infection & Immunity*. 64:3310-7
18. Fazekas de St. Groth, Webster RG (1966) Disquisitions of Original Antigenic Sin. I. Evidence in man. *J Exp Med* 124:331-45
19. Jackson DC, Tang XL, Brown LE, Murray JM, White DO, Tregear GW
- 25 (1986) Antigenic determinants of influenza virus hemagglutinin. XII. the epitopes of a synthetic peptide representing the C-terminus of HA1. *Virology* 155:625-32
20. Burrell DH (1983) Caseous lymphadenitis vaccine *NSW Vet. Proc.* 19, 53-57
- 30 21. Hodgson AL, Krywult J, Corner LA, Rothel JS, Radford AJ (1992) Rational attenuation of *Corynebacterium pseudotuberculosis*: potential cheesy gland vaccine and live delivery vehicle. *Infect Immun* 60, 2900-2905
22. Hodgson AL, Tachedjian M, Corner LA, Radford AJ (1994) Protection of sheep against caseous lymphadenitis by use of a single oral dose of live
- 35 recombinant *Corynebacterium pseudotuberculosis*. *Infect Immun* 62, 5275-5280



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

(A) NAME: The Council of the Queensland Institute of  
Medical Research  
(B) STREET: 300 Herston Road  
10 (C) CITY: Herston  
(D) STATE: Queensland  
(E) COUNTRY: Australia  
(F) POSTAL CODE (ZIP): 4029

15 (A) NAME: Commonwealth Scientific and Industrial  
Research Organisation  
(B) STREET: Limestone Avenue  
(C) CITY: Campbell  
(D) STATE: ACT  
20 (E) COUNTRY: Australia  
(F) POSTAL CODE (ZIP): 2601

(A) NAME: The University of Melbourne  
25 (B) STREET: Royal Parade  
(C) CITY: Parkville  
(D) STATE: Victoria  
(E) COUNTRY: Australia  
(F) POSTAL CODE (ZIP): 3052

30 (A) NAME: The Walter and Eliza Hall Institute of  
Medical Research  
(B) STREET: Royal Melbourne Hospital, Royal Parade  
(C) CITY: Parkville  
(D) STATE: Victoria  
35 (E) COUNTRY: Australia  
(F) POSTAL CODE (ZIP): 3052

(A) NAME: CSL Limited  
40 (B) STREET: 45 Poplar Road  
(C) CITY: Parkville  
(D) STATE: Victoria  
(E) COUNTRY: Australia  
(F) POSTAL CODE (ZIP): 3052

45 (ii) TITLE OF INVENTION: Enhancement of Immune Response using  
Targeting Molecules

(iii) NUMBER OF SEQUENCES: 1

50 (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
55 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: AU PO 5891  
(B) FILING DATE: 27-MAR-1997

60 (vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: AU PP 1830

(B) FILING DATE: 13-FEB-1998

## (2) INFORMATION FOR SEQ ID NO: 1:

5

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11265 base pairs

(B) TYPE: nucleic acid

10

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

15

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

20	TCTAGAGTCG ACCAATTCTC ATGTTTGACA GCTTATCATC GCAGATCCTG AGCTTGATG	60
	GTGCACTCTC AGTACAATCT GCTCTGCTGC CGCATAGTTA AGCCAGTATC TGCTCCCTGC	120
	TTGTGTGTTG GAGGTCGCTG AGTAGTGCGC GAGCAAAATT TAAGCTACAA CAAGGCAAGG	180
25	CTTGACCGAC AATTGCATGA AGAATCTGCT TAGGGTTAGG CGTTTTCGCG TGCTTCGCGA	240
	TGTACGGGCC AGATATACGC GTATCTGAGG GGAAGTAGGT GTGTTTAGGC GCCCAGCGGG	300
30	GCTTCGGTTG TACGCGGTTA GGAGTCCCCT CAGGATATAG TAGTTTCGCT TTTGCATAGG	360
	GAGGGGGAAA TGTAAGCTTA TGCAATACAC TTGTAGTCTT GCAACATGGT AACGATGAGT	420
	TAGCAACATG CCTTACAAGG AGAGAAAAAG CACCGTGCAT GCCGATTGGT GGAAGTAAGG	480
35	TGGTACGATC GTGCCTTATT AGGAAGGCAA CAGACAGGTC TGACATGGAT TGGACGAACC	540
	ACTGAATTCC GCATTGCAGA GATAATTGTA TTTAAGTGCC TAGCTCGATA CAATAAACGC	600
40	CATTTGACCA TTCACCACAT TGGTGTGCAC CTCCAAGCTG GGTACCAGCT GCTAGCAAGC	660
	TTGCTAGCGG CCGCTCGAGC TCAGCACATT TGCCCCCAG CCATGGCTTG TCTTGGAATC	720
	CGGAGGTACA AAGCTCAACT GCAGCTGCCT TCTAGGACTT GGCCTTTTGT AGCCCTGCTC	780
45	ACTCTTCTTT TCATCCCACT CTTCTCTGAA GCCATACAGG TGACCCAACC TTCAGTGGTG	840
	TTGGCTAGCA GCCATGGTGT CGCCAGCTTT CCATGTGAAT ATTCACCATC ACACAACACT	900
50	GATGAGGTCC GGGTGACTGT GCTGCGGCAG ACAAATGACC AAATGACTGA GGTCTGTGCC	960
	ACGACATTCA CAGAGAAGAA TACAGTGGGC TTCCTAGATT ACCCCTTCTG CAGTGGTACC	1020
	TTTAATGAAA GCAGAGTGAA CCTCACCATC CAAGGACTGA GAGCTGTTGA CACGGGACTG	1080
55	TACCTCTGCA AGGTGGAAC CATGTACCCA CCGCCATACT TTGTGGGCAT GGGCAACGGG	1140
	ACGCAGATTT ATGTCATTGA TCCAGAACCA TGCCCGGATT CTGGTAAGTA TAAGCTTCAG	1200
60	CGCTCCTGCC TGGACGCATC CCGGCTATGC AGCCCCAGTC CAGGGCAGCA AGGCAGGCC	1260
	CGTCTGCCTC TTCACCCGGA GCCTCTGCCC GCCCCACTCA TGCTCAGGGA GAGGGTCTTC	1320
	TGGCTTTTTC CCAGGCTCTG GGCAGGCACA GGCTAGGTGC CCCTAACCCA GGCCCTGCAC	1380
65	ACAAAGGGGC AGGTGCTGGG CTCAGACCTG CCAAGAGCCA TATCCGGGAG GACCCTGCCC	1440

	CTGACCTAAG CCCACCCCAA AGGCCAAACT CTCCACTCCC TCAGCTCGGA CACCTTCTCT	1500
5	CCTCCCAGAT TCCAGTAACT CCCAATCTTC TCTCTGCAGA GCCCAAATCT TGTGACAAAA	1560
	CTCACACATG CCCACCGTGC CCAGGTAAGC CAGCCCAGGC CTCGCCCTCC AGCTCAAGGC	1620
	GGGACAGGTG CCCTAGAGTA GCCTGCATCC AGGGACAGGC CCCAGCCGGG TGCTGACACG	1680
10	TCCACCTCCA TCTCTTCCTC AGCACCTGAA CTCCTGGGGG GACCGTCAGT CTTCCTCTTC	1740
	CCCCCAAAC CCAAGGACAC CCTCATGATC TCCCGGACCC CTGAGGTCAC ATGCGTGGTG	1800
15	GTGGACGTGA GCCACGAAGA CCTGAGGTC AAGTTCAACT GGTACGTGGA CGGCGTGGAG	1860
	GTGCATAATG CCAAGACAAA GCCCGGGGAG GAGCAGTACA ACAGCACGTA CCGGGTGGTC	1920
	AGCGTCCTCA CCGTCCTGCA CCAGGACTGG CTGAATGGCA AGGAGTACAA GTGCAAGGTC	1980
20	TCCAACAAAG CCCTCCAGC CCCCATCGAG AAAACCATCT CCAAAGCCAA AGGTGGGACC	2040
	CGTGGGGTGC GAGGGCCACA TGGACAGAGG CCGGCTCGGC CCACCCTCTG CCCTGAGAGT	2100
25	GACCGCTGTA CCAACCTCTG TCCTACAGGG CAGCCCCGAG AACCACAGGT GTACACCCTG	2160
	CCCCCATCCC GGGATGAGCT GACCAAGAAC CAGGTCAGCC TGACCTGCCT GGTCAAAGGC	2220
	TTCTATCCCA GCGACATCGC CGTGGAGTGG GAGAGCAATG GGCAGCCGGA GAACAACTAC	2280
30	AAGACCACGC CTCCCGTGCT GGACTCCGAC GGCTCCTTCT TCCTCTACAG CAAGCTCACC	2340
	GTGGACAAGA GCAGGTGGCA GCAGGGGAAC GTCTTCTCAT GCTCCGTGAT GCATGAGGCT	2400
35	CTGCACAACC ACTACACGCA GAAGAGCCTC TCCCTGTCTC CGGGTAAATG AGTGCGACGG	2460
	CCGGATCCAG ACATGATAAG ATACATTGAT GAGTTTGGAC AAACCACAAC TAGAATGCAG	2520
	TGAAAAAAT GCTTTATTG TGAAATTTGT GATGCTATTG CTTTATTTGT AACCATTATA	2580
40	AGCTGCAATA AACAAATTAA CAACAACAAT TGCATTCAAT TTATGTTTCA GGTTCAGGGG	2640
	GAGGTGGGGA GGTTTTTTAA AGCAAGTAAA ACCTCTACAA ATGTGGTATG GCTGATTATG	2700
45	ATCCGGCTGC CTCGCGCGTT TCGGTGATGA CGGTGAAAAC CTCTGACACA TGCAGCTCCC	2760
	GGAGACGGTC ACAGCTTGTC TGTAAGCGGA TGCCGGGAGC AGACAAGCCC GTCAGGGCGC	2820
	GTCAGCGGGT GTTGGCGGGT GTCGGGGCGC AGCCATGACC GGTGACCCAC TGGGCGCCAG	2880
50	AAATCCGCGC GGTGGTTTTT GGGGGTCGGG GGTGTTTGGC AGCCACAGAC GCCCGGTGTT	2940
	CGTGTGCGGC CAGTACATGC GGTCCATGCC CAGGCCATCC AAAAACCATG GGTCTGTCTG	3000
55	CTCAGTCCAG TCGTGGACCA GACCCACGC AACGCCCCAA ATAATAACCC CCACGAACCA	3060
	TAAACCATTC CCCATGGGGG ACCCCGTCCC TAACCCACGG GGCCAGTGGC TATGGCAGGG	3120
	CCTGCCGCCC CGACGTTGGC TGCAGCCCT GGGCCTTCAC CCGAACTTGG GGGGTGGGGT	3180
60	GGGGAAAAGG AAGAAACGCG GCGGTATTGG CCCCATTGGG GTCTCGGTGG GGTATCGACA	3240
	GAGTGCCAGC CCTGGGACCG AACCCGCGT TTATGAACAA ACGACCCAAC ACCCGTGCGT	3300
65	TTTATTCTGT CTTTTTATTG CCGTCATAGC GCGGGTTCCT TCCGGTATTG TCTCCTCCG	3360
	TGTTTCAGTT AGCCTCCCCC ATCTCCCTA TTCCTTTGCC CTCGGACGAG TGCTGGGGCG	3420
	TCGGTTTCCA CTATCGGCGA GTACTTCTAC ACAGCCATCG GTCCAGACGG CCGCGCTTCT	3480

	GCGGGCGATT TGTGTACGCC CGACAGTCCC GGCTCCGGAT CGGACGATTG CGTCGCATCG	3540
5	ACCCTGCGCC CAAGCTGCAT CATCGAAATT GCCGTCAACC AAGCTCTGAT AGAGTTGGTC	3600
	AAGACCAATG CGGAGCATAT ACGCCCGGAG CCGCGGCGAT CCTGCAAGCT CCGGATGCCT	3660
	CCGCTCGAAG TAGCGCGTCT GCTGCTCCAT ACAAGCCAAC CACGGCCTCC AGAAGAAGAT	3720
10	GTTGGCGACC TCGTATTGGG AATCCCCGAA CATCGCCTCG CTCCAGTCAA TGACCGCTGT	3780
	TATGCGGCCA TTGTCCGTCA GGACATTGTT GGAGCCGAAA TCCGCGTGCA CGAGGTGCCG	3840
15	GACTTCGGGG CAGTCCTCGG CCCAAAGCAT CAGCTCATCG AGAGCCTGCG CGACGGACGC	3900
	ACTGACGGTG TCGTCCATCA CAGTTTGCCA GTGATACACA TGGGGATCAG CAATCGCGCA	3960
	TATGAAATCA CGCCATGTAG TGTATTGACC GATTCCCTTG GGTCCGAATG GGCCGAACCC	4020
20	GCTCGTCTGG CTAAGATCGG CCGCAGCGAT CGCATCCATG GCCTCCGCGA CCGGCTGCAG	4080
	AACAGCGGGC AGTTCGGTTT CAGGCAGGTC TTGCAACGTG ACACCCTGTG CACGGCGGGA	4140
25	GATGCAATAG GTCAGGCTCT CGCTGAATTC CCCAATGTCA AGCACTTCCG GAATCGGGAG	4200
	CGCGGCCGAT GCAAAGTGCC GATAAACATA ACGATCTTTG TAGAAACCAT CGGCGCAGCT	4260
	ATTTACCCGC AGGACATATC CACGCCCTCC TACATCGAAG CTGAAAGCAC GAGATTCTTC	4320
30	GCCCTCCGAG AGCTGCATCA GGTGCGGAG GCTGTGGAAC TTTTCGATCA GAAACTTCTC	4380
	GACAGACGTC GCGGTGAGTT CAGGCTTTTT CATATCTCAT TGCCCGGGAT CTGCGGCACG	4440
35	CTGTTGACGC TGTTAAGCGG GTCGCTGCAG GGTGCTCGG TGTTCGAGGC CACACGCGTC	4500
	ACCTTAATAT GCGAAGTGGA CCTGGGACCG CGCCGCCCCG ACTGCATCTG CGTGTTCGAA	4560
	TTCCCAATG ACAAGACGCT GGGCGGGGTT TGTGTCATCA TAGAACTAAA GACATGCAAA	4620
40	TATATTTCTT CCGGGGACAC CGCCAGCAAA CGCGAGCAAC GGGCCACGGG GATGAAGCAG	4680
	GGCATGGCGG CCGACGCGCT GGGCTACGTC TTGCTGGCGT TCGCGACGCG AGGCTGGATG	4740
45	GCCTTCCCCA TTATGATTCT TCTCGCTTCC GCGGCGATCG GGATGCCCGC GTTGCAGGCC	4800
	ATGCTGTCCA GGCAGGTAGA TGACGACCAT CAGGGACAGC TTCAAGGATC GCTCGCGGCT	4860
	CTTACCAGCC TAACTTCGAT CACTGGACCG CTGATCGTCA CGGCGATTTA TGCCGCCTCG	4920
50	GCGAGCACAT GGAACGGGTT GGCATGGATT GTAGGCGCCG CCCTATACCT TGTCTGCCTC	4980
	CCCGCGTTGC GTCGCGGTGC ATGGAGCCGG GCCACCTCGA CCTGAATGGA AGCCGGCGGC	5040
55	ACCTCGCTAA CGGATTCACC ACTCCAAGAA TTGGAGCCAA TCAATTCTTG CGGAGAACTG	5100
	TGAATGCGCA AACCAACCTT TGGCAGAACA TATCCATCGC GTCCGCCATC TCCAGCAGCC	5160
	GCACGCGGCG CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA	5220
60	TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA	5280
	CCCACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC	5340
65	TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCTTCGG GAAGCGTGGC	5400
	GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTT GCTCCAAGCT	5460
	GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACATATCG	5520

	TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG	5580
5	GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA	5640
	CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG	5700
	AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT	5760
10	TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT	5820
	TTCTACGGGG TCTGACGCTC ACTGGAACGA AAACCTCACGT TAAGGGATTT TGGTCATGAG	5880
15	ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT	5940
	CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC	6000
	TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC TGAATCCCCG TCGTGTAGAT	6060
20	AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC	6120
	ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG	6180
25	AAGTGGTCCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG	6240
	AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTG CAGGCATCGT	6300
	GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCTAAC GATCAAGGCG	6360
30	AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT	6420
	TGTCAGAAGT AAGTTGGCCG CAGTGTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC	6480
35	TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC	6540
	ATTCTGAGAA TAGTGATGC GCGGACCGAG TTGCTCTTGC CCGGCGTCAA CACGGGATAA	6600
	TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAACGTT CTTCGGGGCG	6660
40	AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC	6720
	CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG	6780
45	GCAAAATGCC GCAAAAAGG GAATAAGGGC GACACGGAAA TGTGAATAC TCATACTCTT	6840
	CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT	6900
	TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCCC GAAAAGTGCC	6960
50	ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAAATA GCGGTATCAC	7020
	GAGGCCCTTT CGTCTTCAAG AATTCTCATG TTTGACAGCT TATCATCGAT AAGCTGATCC	7080
55	TCACAGGCCG CACCCAGCTT TTCTTCCGTT GCCCCAGTAG CATCTCTGTC TGGTGACCTT	7140
	GAAGAGGAAG AGGAGGGGTC CCGAGAAATC CCATCCCTAC CGTCCAGCAA AAAGGGGGAC	7200
	GAGGAATTTG AGGCCTGGCT TGAGGCTCAG GACGCAAATC TTGAGGATGT TCAGCGGGAG	7260
60	TTTTCCGGGC TCGAGTAAT TGGTGATGAG GACGAGGATG GTTCGGAGGA TGGGGAATTT	7320
	TCAGACCTGG ATCTGTCTGA CAGCGACCAT GAAGGGGATG AGGGTGGGGG GGCTGTTGGA	7380
65	GGGGGCAGGA GTCTGCACTC CCTGTATTCA CTGAGCGTCG TCTAATAAAG ATGTCTATTG	7440
	ATCTCTTTTA GTGTGAATCA TGTCTGACGA GGGGCCAGGT ACAGGACCTG GAAATGGCCT	7500
	AGGAGAGAAG GGAGACACAT CTGGACCAGA AGGCTCCGGC GGCAGTGGAC CTCAAAGAAG	7560

	AGGGGGTGAT AACCATGGAC GAGGACGGGG AAGAGGACGA GGACGAGGAG GCGGAAGACC	7620
5	AGGAGCCCCG GCGGGCTCAG GATCAGGGCC AAGACATAGA GATGGTGTCC GGAGACCCCA	7680
	AAAACGTCCA AGTTGCATTG GCTGCAAAGG GACCCACGGT GGAACAGGAG CAGGAGCAGG	7740
	AGCGGGAGGG GCAGGAGCAG GAGGGGCAGG AGGGAGGCCG GGGTCGAGGA GGTAGTGGAG	7800
10	GCCGGGGTCG AGGAGGTAGT GGAGGCCGCC GGGGTAGAGG ACGTGAAAGA GCCAGGGGGG	7860
	GAAGTCGTGA AAGAGCCAGG GGGAGAGGTC GTGGACGTGG AGAAAAGAGG CCCAGGAGTC	7920
15	CCAGTAGTCA GTCATCATCA TCCGGGTCTC CACCGCGCAG GCCCCCTCCA GGTAGAAGGC	7980
	CATTTTTCCTA CCCTGTAGGG GAAGCCGATT ATTTTGAATA CCACCAAGAA GGTGGCCCTCAG	8040
	ATGGTGAGCC TGACGTGCCC CCGGGAGCGA TAGAGCAGGG CCCCAGCAGT GACCCAGGAG	8100
20	AAGGCCCAAG CACTGGACCC CGGGGTCAGG GTGATGGAGG CAGGCGCAAA AAAGGAGGGT	8160
	GGTTTGAAAA GCATCGTGGT CAAGGAGGTT CCAACCCGAA ATTTGAGAAC ATTGCAGAAG	8220
25	GTTTAAGAGC TCTCCTGGCT AGGAGTCACG TAGAAAGGAC TACCGACGAA GGAACCTGGG	8280
	TCGCCGGTGT GTTCGTATAT GGAGGTAGTA AGACCTCCCT TTACAACCTA AGGCGAGGAA	8340
	CTGCCCTTGC TATTCCACAA TGTCGTCTTA CACCATTGAG TCGTCTCCCC TTTGGAATGG	8400
30	CCCCTGGACC CGGCCACAA CCTGGCCCGC TAAGGGAGTC CATTGTCTGT TATTTCATGG	8460
	TCTTTTACAA AACTCATATA TTTGCTGAGG TTTTGAAGGA TGCGATTAAAG GACCTTGTTA	8520
35	TGACAAAGCC CGCTCCTACC TGCAATATCA GGGTGACTGT GTGCAGCTTT GACGATGGAG	8580
	TAGATTTGCC TCCCTGGTTT CCACCTATGG TGGAAAGGGC TGCCCGGGAG GGTGATGACG	8640
	GAGATGACGG AGATGAAGGA GGTGATGGAG ATGAGGGTGA GGAAGGGCAG GAGTGTGTGA	8700
40	ACTTGTAGG AGACGCCCTC AATCGTATTA AAAGCCGTGT ATTCCCCCGC ACTAAAGAAT	8760
	AAATCCCCAG TAGACATCAT GCGTGCTGTT GGTGTATTTT TGGCCATCTG TCTTGTACC	8820
45	ATTTTCGTCC TCCCAACATG GGGCAATTGG GCATACCCAT GTTGTACGT CACTCAGCTC	8880
	CGCGCTCAAC ACCTTCTCGC GTTGGAAAAC ATTAGCGACA TTTACCTGGT GAGCAATCAG	8940
	ACATGCGACG GCTTTAGCCT GGCTCCTTA AATTCACCTA AGAATGGGAG CAACCAGCAT	9000
50	GCAGGAAAAG GACAAGCAGC GAAAATTCAC GCCCCCTTGG GAGGTGGCGG CATATGCAAA	9060
	GGATAGCACT CCCACTCTAC TACTGGGTAT CATATGCTGA CTGTATATGC ATGAGGATAG	9120
55	CATATGCTAC CCGGATACAG ATTAGGATAG CATATACTAC CCAGATATAG ATTAGGATAG	9180
	CATATGCTAC CCAGATATAG ATTAGGATAG CCTATGCTAC CCAGATATAA ATTAGGATAG	9240
	CATATACTAC CCAGATATAG ATTAGGATAG CATATGCTAC CCAGATATAG ATTAGGATAG	9300
60	CCTATGCTAC CCAGATATAG ATTAGGATAG CATATGCTAC CCAGATATAG ATTAGGATAG	9360
	CATATGCTAT CCAGATATTT GGGTAGTATA TGCTACCCAG ATATAAATTA GGATAGCATA	9420
65	TACTACCCTA ATCTCTATTA GGATAGCATA TGCTACCCGG ATACAGATTA GGATAGCATA	9480
	TACTACCCAG ATATAGATTA GGATAGCATA TGCTACCCAG ATATAGATTA GGATAGCCTA	9540
	TGCTACCCAG ATATAAATTA GGATAGCATA TACTACCCAG ATATAGATTA GGATAGCATA	9600

	TGCTACCCAG ATATAGATTA GGATAGCCTA TGCTACCCAG ATATAGATTA GGATAGCATA	9660
5	TGCTATCCAG ATATTTGGGT AGTATATGCT ACCCATGGCA ACATTAGCCC ACCGTGCTCT	9720
	CAGCGACCTC GTGAATATGA GGACCAACAA CCCTGTGCTT GGCCTCAGG CGCAAGTGTG	9780
	TGTAATTTGT CCTCCAGATC GCAGCAATCG CGCCCTATC TTGGCCCGCC CACCTACTTA	9840
10	TGCAGGTATT CCCCAGGGTG CCATTAGTGG TTTTGTGGGC AAGTGGTTG ACCGCAGTGG	9900
	TTAGCGGGT TACAATCAGC CAAGTTATTA CACCCTTATT TTACAGTCCA AAACCGCAGG	9960
15	GCGGCGTGTG GGGGCTGACG CGTGCCCCA CTCCACAATT TCAAAAAAA GAGTGCCAC	10020
	TTGTCTTTGT TTATGGGCC CATTGGCGTG GAGCCCCGT TAATTTTCGG GGGTGTAGA	10080
	GACAACCACT GGAGTCCGCT GCTGTGCGCG TCCACTCTCT TTCCCCTTGT TACAAATAGA	10140
20	GTGTAACAAC ATGGTTCACC TGTCTTGCTC CTGCGCTGGG ACACATCTTA ATAACCCAG	10200
	TATCATATTG CACTAGGATT ATGTGTTGCC CATAGCCATA AATTCGTGTG AGATGGACAT	10260
25	CCAGTCTTTA CGGCTTGTC CCACCCCATG GATTTCCTATT GTTAAAGATA TTCAGAATGT	10320
	TTCATTCTTA CACTAGTATT TATTGCCCAA GGGGTTTGTG AGGGTTATAT TGGTGTGATA	10380
	GCACAATGCC ACCACTGAAC CCCCCGTCCA AATTTTATTC TGGGGGCGTC ACCTGAAACC	10440
30	TTGTTTTCGA GCACCTCACA TACACCTTAC TGTCACAAC TCAGCAGTTA TTCTATTAGC	10500
	TAAACGAAGG AGAATGAAGA AGCAGGCGAA GATTCAGGAG AGTTCCTGC CCGCTCCTTG	10560
35	ATCTTCAGCC ACTGCCCTTG TGACTAAAAT GGTCCTACTC CCTCGTGGA TCCTGACCCC	10620
	ATGTAAATAA AACCGTGACA GCTCATGGGG TGGGAGATAT CGCTGTTCCT TAGGACCCTT	10680
	TTACTAACCC TAATTCGATA GCATATGCTT CCCGTTGGGT AACATATGCT ATTGAATTAG	10740
40	GGTTAGTCTG GATAGTATAT ACTACTACCC GGAAGCATA TGCTACCCGT TTAGGGTTAA	10800
	CAAGGGGGCC TTATAAACAC TATTGCTAAT GCCCTCTTGA GGGTCCGCTT ATCGGTAGCT	10860
45	ACACAGGCCC CTCTGATTGA CGTTGGTGTA GCCTCCCGTA GTCTTCCTGG GCCCTGGGA	10920
	GGTACATGTC CCCCAGCATT GGTGTAAGAG CTTCAGCCAA GAGTTACACA TAAAGGCAAT	10980
	GTTGTGTTGC AGTCCACAGA CTGCAAAGTC TGCTCCAGGA TGAAAGCCAC TCAGTGTGG	11040
50	CAAATGTGCA CATCCATTTA TAAGGATGTC AACTACAGTC AGAGAACCCC TTTGTGTTG	11100
	GTCCCCCCCC GTGTCACATG TGAACAGGG CCCAGTTGGC AAGTTGTACC AACCAACTGA	11160
55	AGGGATTACA TGCACTGCCC CGAATACAAA ACAAAGCGC TCCTCGTACC AGCGAAGAAG	11220
	GGGCAGAGAT GCCGTAGTCA GGTTTAGTTC GTCCGGCGGC GGGGC	11265

## CLAIMS:

1. A DNA molecule for use in raising an immune response to an antigen, the DNA molecule including a first sequence encoding a targeting molecule,  
5 a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerisation or multimerisation of the product encoded by the DNA molecule.
2. A DNA molecule as claimed in claim 1 in which the antigen or epitope  
10 thereof encoded by the second sequence is a polypeptide which promotes dimerisation or multimerisation of the product encoded by the DNA molecule and the third sequence is absent.
3. A DNA molecule as claimed in claim 1 in which the third sequence is present.
- 15 4. A DNA molecule as claimed in any one of claims 1 to 3 in which the targeting molecule encoded by the first sequence is a ligand which targets lymphoid cells, lymphoid sites or antigen presenting cells.
5. A DNA molecule as claimed in any one of claims 1 to 4 in which the targeting molecule encoded by the first sequence is selected from the group  
20 consisting of CTLA4, L-selectin, CD40L, OX40, CD28, and antibodies to receptors on antigen presenting cells.
6. A DNA molecule as claimed in any one of claims 1 to 5 in which the targeting molecule encoded by the first sequence is CTLA4.
7. A polypeptide, the polypeptide being encoded by the DNA molecule  
25 as claimed in any one of claims 1 to 6.
8. A vector including the DNA molecule as claimed in any one of claims 1 to 6.
9. A composition for use in raising an immune response in an animal the composition including the DNA molecule as claimed in any one of claims 1  
30 to 6 or the vector as claimed in claim 8 and an acceptable diluent or excipient.
10. A composition for use in raising an immune response in an animal the composition including the polypeptide as claimed in claim 7 and an acceptable diluent or excipient.



11. A method of raising an immune response in an animal, the method comprising administering to the animal the composition as claimed in claim 9 or claim 10.
12. A method of deviating the immune response to an antigen in an individual, the method comprising administering to the individual a DNA molecule including a first sequence encoding CTLA4, a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerisation or multimerisation of the product encoded by the DNA molecule.
13. A method as claimed in claim 12 in which the antigen or epitope thereof encoded by the second sequence is a polypeptide which promotes dimerisation or multimerisation of the product encoded by the DNA molecule and the third sequence is absent.
14. A method as claimed in claim 12 in which the third sequence is present.

1/20




FIGURE 1

2/20




FIGURE 2

3/20




FIGURE 3

4/20




FIGURE 4

5/20




FIGURE 5

6/20




FIGURE 6

7/20




FIGURE 7



8/20




FIGURE 8

9/20




FIGURE 9

10/20




FIGURE 10

11/20




FIGURE 11

12/20




FIGURE 12

13/20




FIGURE 13

14/20




FIGURE 14

15/20




FIGURE 15



16/20




FIGURE 16

17/20




FIGURE 17

18/20




FIGURE 18




FIGURE 19

20/20




FIGURE 20

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 98/00208

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>				
Int Cl <sup>6</sup> : C12N 15/62; C07K 19/00; A61K 39/00, 48/00				
According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>				
Minimum documentation searched (classification system followed by classification symbols) WPAT, CHEM ABS see below				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched MEDLINE see below				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPAT (C12N-015/62/1C OR C07K-019/1C) AND (ANTIGEN: OR EPITOPE# OR IMMUNOGEN:) AND [(TARGET: OR DIRECT) OR (DIMER: OR MULTIMER: OR OLIGOMER:)] MEDLINE and CHEM ABS: [(FUSION OR HYBRID OR CHIMAER? OR CHIMER?) 2ON (IMMUNOGEN? OR EPITOPE OR ANTIGEN?)] AND (ADJUVANT OR VACCIN? OR (IMMUNE RESPONSE)) AND TARGET?				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
P, X	US 5 698 679 A (NATIONAL JEWISH CENTRE FOR IMMUNOLOGY AND RESPIRATORY MEDICINE) 16 December 1997 see column 8 line 11 - column 10 line 23 column 10 lines 4-14	1, 2, 4-11		
X	WO 96 40941 A (CONNAUGHT LABORATORIES) 19 December 1996 see page 4 lines 7-35, page 11 line 35 - page 13 line 33	1, 2, 4, 5, 7-11		
P, X	Nature, vol. 392, March 1998 pages 408-411 Boyle, J. S. et al. "Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction" see whole document	1-14		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex				
<table border="0"> <tr> <td style="vertical-align: top;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p> </td> </tr> </table>			<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>			
Date of the actual completion of the international search 28 April 1998		Date of mailing of the international search report - 6 MAY 1998		
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer  JIM CHAN Telephone No.: (02) 6283 2340		

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 98/00208

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. Biol. Chem. vol. 271, No. 52, 1996 pages 33670-33677. Cortes, B. et al. "A Pathogen-specific epitope inserted into recombinant secretory immunoglobulin A is immunogenic by the oral route" see Introduction and Discussion	1, 2, 4, 5, 7-11
X	J. Clin. Invest. Vol. 98, no. 9, 1996 pages 2001-2007 Liu, C. et al. "Fc $\gamma$ RI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes". Results page 2003 and Discussion pages 2006-7	1, 2, 4-11
X	Immunotechnology Vol. 2, 1996 pages 85-95 Brumeau, T.D. et al. "Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes". see figure 3, Introduction and Discussion	1, 2, 4, 5, 7-11
X	J. Virol. Vol. 69, No. 4, 1995 pages 2357-2365 Baier, G. et al. "Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface Immunoglobulin D antibody Fab fragments in vitro". see figure 1, column 2 page 2363 paragraph 2	1, 2, 4-11
X	Recombinant Vectors in Vaccine Development. Dev. Biol. Stand. Vol. 82, 1994 pages 215-227 (ed. Brown, F.) Lebens, M. and Holmgren, J. "Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier". see page 22 paragraph 3 - page 24	1, 2, 4, 7-11

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

**International Application No.**  
**PCT/AU 98/00208**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member	
WO	9640941	AU	61178/96
		EP	833929